Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transplantation. 2013;19(4):411–419. doi:10.1002/lt.23605
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–1493. doi:10.1245/s10434-019-07227-9
   PubMed Web of Science ®Google Scholar
• Mulé S, Galletto Pregliasco A, Tenenhaus A, et al. Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma. Radiology. 2020;295(3):562–571. doi:10.1148/radiol.2020192230
   PubMed Web of Science ®Google Scholar
• Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32(7):1053–1063. doi:10.1111/j.1478-3231.2012.02792.x
   PubMed Web of Science ®Google Scholar
• Mao S, Yu X, Yang Y, et al. Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma. Sci Rep. 2021;11(1):13999. doi:10.1038/s41598-021-93528-7
   Web of Science ®Google Scholar
• Agopian VG, Harlander-Locke MP, Markovic D, et al. Evaluation of patients with hepatocellular carcinomas that do not produce α-Fetoprotein. JAMA Surg. 2017;152(1):55–64. doi:10.1001/jamasurg.2016.3310
   PubMed Web of Science ®Google Scholar
• Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(1):157–164. doi:10.1111/jgh.12438
   PubMed Web of Science ®Google Scholar
• Zhang XF, Qi X, Meng B, et al. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. Eur j Surg Oncol. 2010;36(8):718–724. doi:10.1016/j.ejso.2010.05.022
   PubMed Web of Science ®Google Scholar
• Ang SF, Ng ES, Li H, et al. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10(4):e0118658.
   Web of Science ®Google Scholar
• Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69(6):1284–1293. doi:10.1016/j.jhep.2018.08.027
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39(1):26–42. doi:10.1055/s-0038-1676806
   PubMed Web of Science ®Google Scholar
• Xu L, Yu S, Zhuang L, et al. Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8(21):34954–34960. doi:10.18632/oncotarget.16865
   PubMedGoogle Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
   PubMed Web of Science ®Google Scholar
• Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. doi:10.7717/peerj.7132
   PubMed Web of Science ®Google Scholar
• Cho CS, Gonen M, Shia J, et al. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg. 2008;206(2):281–291. doi:10.1016/j.jamcollsurg.2007.07.031
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Department of Medical Administration NHaHCotPsRoC. [Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)]. Zhonghua Gan Zang Bing Za Zhi. 2020;2(28):112–128. Chinese
   Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Chan AW, Kumada T, Toyoda H, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31(7):1300–1306. doi:10.1111/jgh.13291
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kudo M, et al. Albumin-Bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and child-pugh classifications. Liver Cancer. 2017;6(3):204–215. doi:10.1159/000452846
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103(6):725–734. doi:10.1002/bjs.10095
   PubMed Web of Science ®Google Scholar
• Li MX, Zhao H, Bi XY, et al. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: validation in a Chinese cohort. Hepatol Res. 2017;47(8):731–741. doi:10.1111/hepr.12796
   PubMed Web of Science ®Google Scholar
• Ho SY, Hsu CY, Liu PH, et al. Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Eur j Surg Oncol. 2019;45(5):776–781. doi:10.1016/j.ejso.2018.10.541
   PubMed Web of Science ®Google Scholar
• He W, Peng B, Tang Y, et al. Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol. 2018;16(5):756–764 e710. doi:10.1016/j.cgh.2017.12.002
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
   PubMed Web of Science ®Google Scholar
• Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2(3–4):367–383. doi:10.1159/000343852
   PubMed Web of Science ®Google Scholar
• Chen Q, Li F, Zhong C, et al. Inflammation score system using preoperative inflammatory markers to predict prognosis for hepatocellular carcinoma after hepatectomy: a cohort study. J Cancer. 2020;11(17):4947–4956. doi:10.7150/jca.45274
   PubMed Web of Science ®Google Scholar
• Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5(5):e1093722. doi:10.1080/2162402X.2015.1093722
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Song W, Tian C, Wang K, Zhang RJ, Zou SB. The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: a meta-analysis. Sci Rep. 2017;7:46601. doi:10.1038/srep46601
   PubMed Web of Science ®Google Scholar
• Wu Y, Tu C, Shao C. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy. BMC Surg. 2021;21(1):178. doi:10.1186/s12893-021-01180-9
   PubMed Web of Science ®Google Scholar
• Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–855. doi:10.1053/j.gastro.2009.06.003
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325–339. doi:10.1245/s10434-012-2513-1
   PubMed Web of Science ®Google Scholar
• Wang L, Jin YX, Ji YZ, Mu Y, Zhang SC, Pan SY. Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma. World j Gastroenterol. 2020;26(14):1647–1659. doi:10.3748/wjg.v26.i14.1647
   PubMed Web of Science ®Google Scholar
• Li X, Huang H, Yu X, Chen P, Ouyang J, Huang B. A novel prognostic nomogram based on microvascular invasion and hematological biomarkers to predict survival outcome for hepatocellular carcinoma patients. Surg Oncol. 2020;33:51–57. doi:10.1016/j.suronc.2020.01.006
   PubMed Web of Science ®Google Scholar
• Lee S, Kang TW, Song KD, et al. Effect of Microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564–571. doi:10.1097/SLA.0000000000003268
   PubMed Web of Science ®Google Scholar
• Huang J, Liu FC, Li L, Zhou WP, Jiang BG, Pan ZY. Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. Cancer Med. 2020;9(8):2791–2802. doi:10.1002/cam4.2944
   PubMed Web of Science ®Google Scholar
• Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World j Gastroenterol. 2006;12(48):7725–7736. doi:10.3748/wjg.v12.i48.7725
   Web of Science ®Google Scholar
• Wang Y, Sun K, Shen J, et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy. Cancer Res Treatment. 2019;51(4):1464–1478. doi:10.4143/crt.2018.657
   Google Scholar
• Haruki K, Shiba H, Saito N, et al. Risk stratification using a novel liver functional reserve score of combination prothrombin time-international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery. 2018;164(3):404–410. doi:10.1016/j.surg.2018.02.022
   PubMed Web of Science ®Google Scholar
• Pajouheshnia R, Pestman WR, Teerenstra S, Groenwold RH. A computational approach to compare regression modelling strategies in prediction research. BMC Med Res Methodol. 2016;16(1):107. doi:10.1186/s12874-016-0209-0
   Web of Science ®Google Scholar
• Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: i. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98(9):683–690.
   PubMed Web of Science ®Google Scholar